Acid sphingomyelinase deficiency life expectancy

Overview of Acid Sphingomyelinase Deficiency

Mutations in the SMPD1 gene cause acid sphingomyelinase deficiency (ASMD), an uncommon genetic condition. Sphingomyelin accumulates in the liver, spleen, lungs, and brain, causing minor to life-threatening damage.

What is ASMD?

ASMD is a lysosomal storage disorder, previously known as Niemann-Pick types A and B. Mutations in the SMPD1 gene impair acid sphingomyelinase, thereby inhibiting the breakdown of sphingomyelin. Both parents must carry the faulty gene.

Acid sphingomyelinase

Types of ASMD

Type A (Infantile Neurovisceral): Severe neurological decline, hepatosplenomegaly, and feeding difficulties. Fatal in early childhood (≤3 years)

Type B (Chronic Visceral): Enlarged liver/spleen, lung involvement, growth delay, minimal neurological symptoms. Survival into adulthood; lifespan shortened depending on severity

Intermediate forms: Overlap of A & B features. Variable; prognosis depends on organ involvement. 

Symptoms

• Liver and spleen enlargement, abdominal distension
• Lung involvement causes breathing problems
• Developmental delay, feeding issues, hypotonia
• Slow growth, frequent illnesses, tiredness

Important Considerations

• Extremely rare, however, Ashkenazi Jews have a higher prevalence.
• Type A is lethal in infancy, but Type B can live near-normal with problems.
• The overlap with other lysosomal storage diseases often leads to misdiagnosis, which can result in delayed treatment and worsening of symptoms in affected individuals. Genetic testing must begin early.

Also, read https://www.icliniq.com/articles/genetic-disorders/sphingomyelinase-deficiency

What causes sphingomyelinase deficiency?

Mutations in the SMPD1 gene limit acid sphingomyelinase synthesis or function. This enzyme generally breaks down sphingomyelin, a fatty material found in cell membranes. Without it, sphingomyelin builds up in the liver, spleen, lungs, and brain, causing illness.

Genes Cause

• Gene: SMPD1 (chromosome 11).
• Mutation reduces acid sphingomyelinase activity.
• Inability to digest sphingomyelin causes toxic accumulation in lysosomes.
• Autosomal recessive inheritance requires both parents to carry and pass on the defective gene.

Pathophysiology

• Normal function: Acid sphingomyelinase, an enzyme, converts sphingomyelin, a type of fat molecule, to ceramide and phosphocholine.
• Deficiency: Sphingomyelin stores in lysosomes.
• The condition can lead to progressive organ damage, including hepatosplenomegaly, lung disease, and significant neurological degeneration.

Possible Risks

• Genetic background: Ashkenazi Jews have a higher prevalence.
• Family history: 25% of carrier parents' children get ASMD.

Life expectancy with ASMD?

The severe infantile form (Type A) of Acid Sphingomyelinase Deficiency (ASMD) typically results in death by ages 2 to 3, while the chronic visceral form (Type B) can let a person live into adulthood but with lung problems and enlarged organs.

Types and Prognosis

• Infantile Neurovisceral Type AHepatosplenomegaly, severe neurological deterioration, feeding issues Death in early childhood (≤3 years)
• Type B (Chronic Visceral): Liver/spleen enlargement, lung involvement, developmental delay, and a few neurological symptoms. The disease typically survives until adulthood, but its severity can shorten its lifespan.
• Intermediate forms: A-B overlap. Variable; organ involvement determines prognosis

Impacts on Life Expectancy

• Mutations in SMPD1 can induce full enzyme loss (Type A) or partial activity (Type B).
• Lung disease and liver failure cause most Type B morbidity.
• Access to treatment: Supportive care and new medicines, such as enzyme replacement therapy, help patients with SMPD1 mutations feel better, especially with symptoms related to lung disease and liver failure.
• Genetic testing and surveillance can help diagnose and treat issues early.

Effects of New Treatments

• Olipudase alfa (enzyme replacement therapy): Reduces spleen/liver size and improves lung function; recently approved in several places.
• While not a cure, it may enhance Type B patients' life expectancy and quality of life.

Challenges and Risks

• Present medicines cannot treat type A; only supportive care is available.
• Even with treatment, type B patients may have chronic respiratory, hepatic, and stamina difficulties.
• Variable progression: Type B adults might live near-normal lives or develop major issues earlier.

The diagnosis of acid sphingomyelinase deficiency

To diagnose acid sphingomyelinase deficiency (ASMD), doctors check how the organs are working, test enzyme activity, and due to emerging treatments like enzyme replacement therapy, early diagnosis is critical.

Important Diagnostic Methods

1. Enzyme Test

• The enzyme test measures the activity of white blood cells or cultured fibroblast acid sphingomyelinase.
• Biochemical deficiency is confirmed by low or missing activity.
• ASMD is commonly diagnosed using this test first.

2. Gene Testing

• Identifies SMPD1 gene mutations.
• The process confirms the diagnosis and distinguishes between Type A (infantile neurovisceral) and Type B (chronic visceral) diseases.
• This process is beneficial for the identification of carriers and the prenatal diagnosis of known mutant families.

3. Clinical Assessment

• Physical exam: Hepatosplenomegaly (enlargement of the liver and spleen), growth delay, and lung problems.
• Neurological assessment: Developmental regression in Type A.
• Image (MRI/CT): Shows organ hypertrophy and lung involvement.

4. Supportive Tests

• Lipid profiles may be abnormal in blood testing.
• Tissue lipid buildup is revealed via biopsy (rarely used today).
• Assess Type B lung involvement with pulmonary function testing.

Challenges in diagnosing

• Lysosomal storage disorders like Gaucher and Niemann-Pick type C share symptoms.
• Without enzyme and genetic testing, misdiagnosis is common.
• Family counselling and treatment eligibility depend on early detection.

Why Early Diagnosis Matters

• A: Rapid progression; supportive care only.
• Type B: Slower advancement; Olipudase alfa increases lung function and organ size.
• Genetic counselling: Informs families about hereditary hazards and pregnancy planning.

Management & Treatment

The video explains the challenges of treating rare diseases.

• Symptom management: Respiratory assistance, dietary therapy.
• The first disease-specific medication, olipudase alfa (licensed in some places), reduces spleen/liver size and improves lung function.
• Experimental methods: Gene and substrate reduction therapy are being studied.
• Paediatricians, geneticists, pulmonologists, and neurologists handle patients together.

Prevention of acid sphingomyelinase deficiency

Mutations in the SMPD1 gene cause acid sphingomyelinase deficiency (ASMD), which cannot be "prevented." However, there are crucial family risk and inheritance management measures.

Ways to prevent

1. Genetic Advice

1. Families with ASMD should see a genetic counsellor.
2. Counsellors explain autosomal recessive inheritance and child dangers.
3. Informs parents' reproductive decisions.

2. Carrier Test

• Determines SMPD1 gene mutations in parents.
• Healthy carriers can convey the mutation to children.
• If both parents are carriers, each child has a 25% ASMD risk.

3. Prenatal/Preimplantation Testing

• Prenatal testing: CVS or amniocentesis can detect ASMD in fetuses.
• With IVF, preimplantation genetic diagnosis (PGD) selects embryos without mutations.
• These methods prevent illness transmission in families.

4. Population Screening

• In high-prevalence cultures like Ashkenazi Jews, carrier screening programs identify at-risk couples before pregnancy.
• Prevention for already diagnosed patients involves early detection of consequences (lung disease, liver malfunction) and urgent supportive care or enzyme replacement therapy.

ASMD complications

Acid Sphingomyelinase Deficiency (ASMD) causes organ damage from sphingomyelin buildup in the liver, spleen, lungs, and possibly the neurological system. Infantile (Type A) or chronic visceral (Type B) forms affect severity.

Complications major

1. Liver/Spleen

• Hepatosplenomegaly: Liver and spleen enlargement define it.
• Fibrosis and cirrhosis can result from liver disease.
• Anaemia and thrombocytopenia result from hypersplenism.

2. Pulmonary 

• Alveolar macrophage lipid buildup causes interstitial lung disease.
• Interstitial lung disease is characterized by progressive shortness of breath and low oxygen saturation.
• Repeated infections: Pneumonia and bronchopneumonia are common and deadly.
• Chronic pulmonary illness causes right-sided heart failure.

3. Type-A neurological

• Developmental regression: Cognitive and motor decline.
• Hypotonia: Muscle weakness.
• Retinal cherry-red spot: Rare but classic.
• Neurodegeneration kills in early childhood.

4. Metabolic/Hematologic

• Hypersplenism causes anaemia and thrombocytopenia.
• Dyslipidemia raises CVD risk.

5. Bones and Growth

• Growth delay: Kids struggle.
• Patients may have skeletal deformities.

Long-term risks

• Type A: Rapid progression, mortality by ages 2-3.
• Chronic consequences (lung illness, liver fibrosis, cardiovascular risk) in Type B lead to a shorter but unpredictable lifetime.
• Intermediate forms: Mutation and organ involvement determine severity.

Conclusion

Acid sphingomyelinase deficiency is a rare genetic condition that affects how the body stores certain substances. The buildup of sphingomyelin in important organs leads to a range of health issues, from severe problems in infants (Type A) to long-lasting issues in adults (Type B), which can allow them to live into adulthood but still face. Enzyme replacement therapy (Olipudase alfa) may improve the quality of life and survival.

Though serious, ASMD is becoming manageable. Patients with Type B can now receive targeted therapy, while those with Type A cannot. Prompt diagnosis, genetic counselling, and multidisciplinary care prevent problems and enhance results.